Illustrative packaging · Research use only
Tissue repair & growth axis
HGH Fragment 176-191
Choose a specification
1 pack · 10 vials total
Guest checkout is available. Create an account before your first request to receive the eligible 15% welcome offer.
Choose your payment method at checkout to see the total and next payment steps. No administration or personal-use guidance is provided.
Specification review: Confirm the supplied sequence. HGH Fragment 176-191 and modified analogues such as AOD9604 should not be assumed interchangeable.
Molecular docking and breast-cancer cell-line formulation study
What the research examines
A primary study examined a preparation combining an hGH 176-191 peptide with doxorubicin-loaded chitosan nanoparticles. Docking simulations and MCF-7 cell-viability experiments compared the dual-loaded preparation with the drug-loaded carrier alone.
Potential research applications
Possible questions concern peptide–carrier interactions, how loading changes formulation behavior and whether computational binding predictions correspond to cell-based endpoints.
These are research questions drawn from the cited work, not established applications of this supplied material.
Evidence limits
The cited work concerns a multi-component nanoparticle preparation, not isolated peptide effects or clinical outcomes. It does not support a fat-loss claim, and AOD9604 evidence should not be substituted for sequence-matched evidence.
Material identity and presentation
Powder vial artwork is conceptual; actual form and packaging unverified. Published findings do not establish the identity, purity or performance of an individual supplied material.
